Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 997 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Inhibition Clear all
Active, not recruiting Phase 2 Interventional

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

NCT02407405
View directory record Official record
Conditions
Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (PN)
Interventions
Selumetinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 19, 2026, 4:21 AM EDT
Terminated Phase 1 Interventional

ALPN-202 With PD-1 Inhibition in Advanced Malignancies

NCT04920383
View directory record Official record
Conditions
Advanced Solid Tumor, Lymphoma
Interventions
ALPN-202, pembrolizumab KEYTRUDA®
Drug
Lead sponsor
Alpine Immune Sciences, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Grand Rapids, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 2 Interventional Results available

Confirming The Sitaxsentan Dose In Patients Undergoing Heart Surgery

NCT00838383
View directory record Official record
Conditions
Cardiac Surgery Subjects, Subjects Undergoing CABG and/or Cardiac Valve Replacement
Interventions
sitaxsentan (Thelin), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
48 Years to 82 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Charleston, South Carolina • Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Oct 19, 2026, 4:21 AM EDT
Recruiting Phase 1 Interventional

Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer

NCT07645651
View directory record Official record
Conditions
Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
Interventions
Samuraciclib, Computed Tomography, Endoscopic Ultrasound Biopsy, Biospecimen Collection
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 1 Interventional

CIML NK Cell in Head & Neck Cancer

NCT04290546
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
Interleukin-15 Superagonist (N-803), CIML NK cell Infusion, Ipilimumab, Cetuximab
Drug · Biological
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 19, 2026, 4:21 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)

NCT05038020
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
AKST4290, Placebo
Drug
Lead sponsor
Alkahest, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
17
States / cities
Phoenix, Arizona • Glendale, California • Huntington Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 19, 2026, 4:21 AM EDT
Terminated Phase 1 Interventional

A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease

NCT03132324
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
INCB059872
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Miami, Florida • Tamarac, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Oct 19, 2026, 4:21 AM EDT
Recruiting Not applicable Interventional

Reward Processing and Exposure Therapy for Social Anxiety Disorder

NCT06776991
View directory record Official record
Conditions
Social Anxiety Disorder (Social Phobia), Public Speaking Anxiety, Anhedonia, ANXIETY DISORDERS (or Anxiety and Phobic Neuroses), Phobic Disorders
Interventions
Positive Affect Treatment - Behavioral (PAT-B), Relaxation Treatment, Exposure Therapy
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 19, 2026, 4:21 AM EDT
Terminated Not applicable Interventional Results available

Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes

NCT02134717
View directory record Official record
Conditions
Sarcoidosis
Interventions
all subjects will receive maraviroc 300mg orally twice a day for 6 weeks, Bronchoscopy with bronchoalveolar lavage, venipunctures, Skin biopsy
Drug · Procedure
Lead sponsor
Kevin F. Gibson
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 1Phase 2 Interventional

Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

NCT02257424
View directory record Official record
Conditions
Advanced BRAF Mutant Melanoma
Interventions
Trametinib 2 mg daily, hydroxychloroquine (HCQ), dabrafenib 150 mg orally twice a day
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
4
States / cities
Chicago, Illinois • St Louis, Missouri • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

NCT04255433
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Tirzepatide, Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
13,299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
121
States / cities
Birmingham, Alabama • Concord, California • Covina, California + 106 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 19, 2026, 4:21 AM EDT
Withdrawn Phase 2 Interventional

Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)

NCT02962804
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Nivolumab, Radiation
Drug · Radiation
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Oct 19, 2026, 4:21 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

NCT05063552
View directory record Official record
Conditions
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Lip and Oral Cavity Carcinoma, Metastatic Nasal Cavity Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Pharyngeal Squamous Cell Carcinoma, Metastatic Sinonasal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Pharyngeal Squamous Cell Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
Interventions
Atezolizumab, Bevacizumab, Biospecimen Collection, Carboplatin, Cetuximab, Cisplatin, Computed Tomography, Docetaxel, Echocardiography Test, Magnetic Resonance Imaging, Positron Emission Tomography
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
172
States / cities
Little Rock, Arkansas • Dublin, California • Emeryville, California + 135 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers

NCT05928585
View directory record Official record
Conditions
Immune System Diseases, Autoimmunity
Interventions
HIB210, Placebo
Drug
Lead sponsor
HI-Bio, A Biogen Company
Industry
Eligibility
19 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 1Phase 2 Interventional

An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer

NCT02917993
View directory record Official record
Conditions
Lung Cancer
Interventions
Itacitinib, Osimertinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
23
States / cities
La Jolla, California • San Francisco, California • Whittier, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 4 Interventional Results available

Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI

NCT03247738
View directory record Official record
Conditions
ST Segment Elevation Myocardial Infarction, Percutaneous Coronary Intervention
Interventions
Cangrelor, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 3 Interventional

Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR) (BY9010/M1-408)

NCT00659048
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Ciclesonide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2016 · Synced Oct 19, 2026, 4:21 AM EDT
Not yet recruiting Phase 2 Interventional

OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition

NCT05425576
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
OT-101
Drug
Lead sponsor
Oncotelic Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of PDE5 Inhibition on Adipose Metabolism in Humans

NCT04684589
View directory record Official record
Conditions
Obesity
Interventions
Tadalafil 20 MG, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
19 Years to 50 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 19, 2026, 4:21 AM EDT
Terminated Phase 2 Interventional Results available

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

NCT02587650
View directory record Official record
Conditions
ALK Fusion Protein Expression, BRAF wt Allele, Invasive Skin Melanoma, MET Fusion Gene Positive, NRAS wt Allele, NTRK1 Fusion Positive, NTRK2 Fusion Positive, NTRK3 Fusion Positive, RET Fusion Positive, ROS1 Fusion Positive, Stage III Cutaneous Melanoma, Stage IIIA Cutaneous Melanoma, Stage IIIB Cutaneous Melanoma, Stage IIIC Cutaneous Melanoma, Stage IV Cutaneous Melanoma
Interventions
Capmatinib, Ceritinib, Entrectinib, Laboratory Biomarker Analysis, Regorafenib
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Feasibility Trial for Inhibitory-Control Training to Reduce Cocaine Use

NCT02444208
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Active Inhibitory Control Training, Neutral Inhibitory Control Training
Behavioral
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 19, 2026, 4:21 AM EDT
Terminated Phase 3 Interventional Results available

Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

NCT01041781
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, celecoxib, gemcitabine hydrochloride, pemetrexed disodium, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
400
States / cities
Anniston, Alabama • Scottsdale, Arizona • Jonesboro, Arkansas + 266 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

NCT03711058
View directory record Official record
Conditions
Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor, Microsatellite Stable (MSS) Colon Cancer
Interventions
Copanlisib, Nivolumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 19, 2026, 4:21 AM EDT
Completed Phase 2 Interventional Results available

Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma

NCT03396952
View directory record Official record
Conditions
Stage III Cutaneous Melanoma, Stage IIIA Cutaneous Melanoma, Stage IIIB Cutaneous Melanoma, Stage IIIC Cutaneous Melanoma, Stage IV Cutaneous Melanoma
Interventions
Aspirin, Ipilimumab, Laboratory Biomarker Analysis, Pembrolizumab
Drug · Biological · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
19 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 19, 2026, 4:21 AM EDT